Published • loading... • Updated
Canada’s Drug Agency recommends funding drug for early-stage Alzheimer’s disease
The agency said eligible patients must have mild cognitive impairment and confirmed amyloid, while treatment costs about $32,000 a year.
- On Thursday, Canada's Drug Agency recommended that public drug plans cover lecanemab for early-stage Alzheimer's disease, reversing its February position against public funding.
- After Tokyo-based Eisai Co., Ltd. requested reconsideration, the Canadian Drug Expert Committee found it may have underestimated lecanemab's clinical meaningfulness and received new information to address an important clear gap in evidence.
- Lecanemab is an antibody targeting amyloid plaque buildup in the brain, administered intravenously every two or four weeks to patients 50 and older with mild cognitive impairment or mild dementia, requiring regular MRI monitoring for brain swelling or microbleeding.
- If finalized, the recommendation will trigger price negotiations with the pan-Canadian Pharmaceutical Alliance, though the committee noted pricing must be significantly reduced; coverage continues after six months and every 12 months thereafter if clinical benefit persists.
- An estimated 772,000 Canadians have dementia, projected to more than double by 2050; Alzheimer's societies say lecanemab costing about $32,000 annually extends quality cognitive function, while Health Canada approved donanemab in May with unclear public coverage prospects.
Insights by Ground AI
31 Articles
31 Articles
The Canada Medicines Agency recommends that public drug plans take care of treatment that has been shown to be effective in slowing the progression of Alzheimer's disease at an early stage, if patients meet certain conditions.
·Montreal, Canada
Read Full Article
The Toronto Star+5 Reposted by 5 other sources
Canada’s Drug Agency recommends funding lecanemab for early-stage Alzheimer’s disease
TORONTO - Canada's Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer's disease if patients meet certain conditions.
·Toronto, Canada
Read Full Article
Winnipeg Free Press+21 Reposted by 21 other sources
Canada's Drug Agency recommends funding lecanemab for early-stage Alzheimer's disease
TORONTO - Canada's Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer's disease if patients meet certain conditions.
·Winnipeg, Canada
Read Full Article
Coverage Details
Total News Sources31
Leaning Left18Leaning Right1Center10Last UpdatedBias Distribution62% Left
Bias Distribution
- 62% of the sources lean Left
62% Left
L 62%
C 35%
Factuality
To view factuality data please Upgrade to Premium
